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Purpose: Magnetic resonance imaging (MRI)-directed stereotactic body radiation
therapy (SBRT) has been established as a safe and effective treatment for prostate cancer.
For patients with contraindications to MRI, CT-urethrogram is an alternative imaging
approach to identify the location of the prostatic apex to guide treatment. This study
sought to evaluate the safety of urethrogram-directed SBRT for prostate cancer.
Methods: Between February 2009 and January 2014, 31 men with clinically localized
prostate cancer were treated definitively with urethrogram-directed SBRT with or without
supplemental intensity-modulated radiation therapy (IMRT) at Georgetown University
Hospital. SBRTwas delivered either as a primary treatment of 35–36.25Gy in five fractions
or as a boost of 19.5Gy in three fractions followed by supplemental conventionally
fractionated IMRT (45–50.4Gy). Toxicities were recorded and scored using the Common
Terminology Criteria for Adverse Events version 4.0 (CTCAE v.4.0).
Results: The median patient age was 70 years with a median prostate volume of
38 cc. The median follow-up was 3.7 years. The patients were elderly (Median age=70),
and comorbidities were common (Carlson comorbidity index 2 in 36%). Seventy-
one percent of patients utilized alpha agonists prior to treatment, and 9.7% had prior
procedures for benign prostatic hyperplasia. The 3-year actuarial incidence rates of
Grade 3 GU toxicity and Grade 2 GI toxicity were 3.2 and 9.7%, respectively, and
there were no Grade 4 or 5 toxicities.
Conclusion: Magnetic resonance imaging is the preferred imaging modality to guide
prostate SBRT treatment. However, urethrogram-directed SBRT is a safe alternative for
the treatment of patients with prostate cancer who are unable to undergo MRI.
Keywords: prostate cancer, SBRT, urethrogram, CyberKnife, magnetic resonance imaging
Abbreviations: ADT, androgen deprivation therapy; AUA, American Urological Association; BED, biologically effective dose;
BPH, benign prostatic hyperplasia; CCI, Charlson comorbidity index; CT, computed tomography; CTV, clinical target volume;
DVH, dose–volume histogram; EQD2, equivalent dose in 2-Gy fractions; EPIC, expanded prostate index composite; GTV,
gross target volume; Gy, Gray; IMRT, intensity-modulated radiation therapy; IRB, Internal Review Board; MCS,Mental Health
Composite Score; MR,magnetic resonance; PCS, Physical Health Composite Score; PTV, planning target volume, SD, standard
deviation; SF, 12, Short Form, 12 Health Survey; SBRT, stereotactic body radiation therapy.
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Introduction
Stereotactic body radiation therapy (SBRT) treats prostate can-
cer with large doses of radiation per fraction (6.5–9Gy) to take
advantage of the postulated radiobiological model of improved
tumor cell kill with decreased normal tissue toxicity (1, 2). It
may be used as a primary treatment for favorable prostate cancer
(3, 4) or as a boost to conventional pelvic radiation therapy in
unfavorable prostate cancer (5, 6). Early clinical results suggest
that these approaches provide high rates of biochemical control
with acceptable toxicity (7–9). Based on the increased convenience
of an abbreviated treatment, SBRT usage is likely to increase.
The goal of prostate SBRT is to treat the entire prostate
and proximal seminal vesicles while limiting radiation dose to
the adjacent critical structures, including the bladder, rectum,
and membranous urethra. Since the prostate apex is commonly
involved with cancer, under-dosing this region would likely
increase the risk of recurrence (10). Also, identification of the
membranous urethra remains critical during treatment planning
as it is the most common location for radiation therapy-induced
strictures (11). However, poor soft tissue resolution of conven-
tional CT scans prevents adequate visualization of the transition
between the prostate apex and membranous urethra (12–14).
Moreover, the utilization of bony and soft tissue anatomical land-
marks to identify these critical structures is difficult and prone to
error and inter-user variability (15, 16). Reliance on a CT scan
alone, therefore, poses the risk of decreased dose to the prostate
apex or increased dose to the membranous urethra. Such an
uncertainty in treatment planning becomes a heightened concern
because the large radiation doses and steep dose gradients charac-
teristic of SBRT – when incorrectly administered – may result in
a high rate of recurrence or urethral stricture.
The standard approach to treatment planning, therefore, uti-
lizes non-invasive magnetic resonance (MR) imaging to delineate
adjacent critical structures, such as the bladder neck, rectum, and
membranous urethra (12, 13). MR imaging better defines the
prostate and reduces the overall target volume by 30% relative
to CT imaging (17, 18). In addition, the prostatic-rectal and
prostatic-bladder interfaces are better defined by MR than by
CT imaging. The membranous urethra, which varies in length,
is clearly visible on a magnetic resonance imaging (MRI). MR
imaging also better defines the prostatic apex, which allows for
dose reduction to the genitourinary diaphragm (GUD).
A dilemma arises when patients with a contraindication to MR
imaging, such as presence of a pacemaker, defibrillator, ormetallic
foreign bodies, present for radiation treatment (19, 20). For these
patients, an alternative imaging modality must be employed. Ure-
thrograms have previously been used to identify the distal extent
of the membranous urethra and the approximate location of the
prostate apex for the treatment of prostate cancer with conven-
tional radiation therapy (21–23). In these studies, the distance
of the membranous urethra from the GUD (beak of the ure-
throgram) to the prostate apex is approximately 1.0–1.5 cm (23–
25), though the distance can significantly vary between patients
(range, 0.5–2.0 cm) (13, 26, 27). While a urethrogram does not
locate the prostate apex directly, an identifiable point that is
anterior and inferior to the prostate can be used to infer the
relative location of the prostate. To the best of our knowledge, no
studies on urethrogram-directed SBRT for prostate cancer have
been published.Herein, we report our toxicity outcomes following
urethogram-directed SBRT for clinically localized prostate cancer.
Materials and Methods
Patient Selection
Patients eligible for study inclusion had prostate cancer treated
with urethrogram-directed SBRT. Patients treated with MRI-
directed SBRT were excluded. Prospectively collected toxicity
data for all patients included in our institutional database were
analyzed with Internal Review Board (IRB) approval. Relative
comorbidity was assessed using the Charlson comorbidity index
(CCI), as previously described (28) with higher scores represent-
ing increased severity.
SBRT Treatment Planning and Delivery
Stereotactic body radiation therapy treatment planning and deliv-
erywere conducted, as previously publishedwithminormodifica-
tions (3, 29). Four to six goldmarkers were placed into the prostate
transrectally or under transrectal ultrasound guidance. Seven days
after fiducial placement, patients underwent a treatment plan-
ning CT scan with a retrograde urethrogram (21). The patient
was placed in a supine position. To conduct the urethrogram,
approximately 8 cc of contrast was injected into the penile uretrhra
and a penile clamp was applied (22, 23). Next, a CT scan using
1.25mm axial slices was completed. The beak of the urethrogram
was defined as the most superior CT slice with contrast in the
urethra. The clinical target volume (CTV), including the prostate
and the proximal seminal vesicles, was defined utilizing this beak
as well as other anatomical landmarks (15, 16). The CTV was
expanded 3mm posteriorly and 5mm in all other dimensions
to create the PTV. The bladder and membranous urethra were
contoured and evaluated with dose–volume histogram (DVH)
analysis during treatment planning usingMultiplan (Accuray Inc.,
Sunnyvale, CA, USA) inverse treatment planning technique, as
previously described (3, 5). Target position was verified multi-
ple times during each treatment using paired, orthogonal x-ray
images (30). An example of a treatment plan is provided in
Figure 1.
Follow-up and Statistical Analysis
Pre-treatment function was documented before treatment (31–
33), and post-treatment toxicity was prospectively recorded
during routine follow-up visits 1month after the completion
of radiation treatment, every 3months for the first year, every
6months for the second and third years, then yearly (3). Toxicity
was documented at follow-up visits using the National Cancer
Institute (NCI) Common Toxicity Criteria for Adverse Events
(CTCAE) version 4.0. Acute toxicity was defined as toxicity expe-
rienced during or within 6months of radiation therapy. Late
toxicity was defined as occurring at least 6months after delivery of
radiation therapy. In general, Grade 2 toxicity is defined as symp-
toms requiring medication (i.e., alpha-antagonist or antidiarrheal
medications) or laser coagulation. Grade 3 toxicity indicates
complications requiring minor surgical intervention (i.e., ure-
thral dilation). Actuarial likelihood estimates for toxicities were
determined using the Kaplan–Meier method.
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FIGURE 1 | A 60-year-old man with intermediate risk prostate cancer
had cardiac disease and an internal defibrillator, which precluded
magnetic resonance imaging for treatment planning. Thus, he was
treated with urethrogram-directed SBRT: treatment planning sagittal
computed tomography urethrogram images demonstrating the prostate (red)
and rectum (green) are shown. Arrowhead marks the “beak” of the
urethrogram. Isodose lines shown as follows: 100% of the prescription dose
(light blue line) and 50% of the prescription dose (dark blue line).
Results
From February 2009 to January 2014, 31 prostate cancer patients
were treated with urethrogram-directed SBRT (Table 1). The
median follow-up was 3.7 years. Patients were ethnically diverse,
with 54.8% of non-Caucasian ancestry. Median age was 70 years
(range, 56–85 years). The most common contraindication to MRI
was a pacemaker/defibrillator (58%). Comorbidities were com-
mon (CCI 2 in 36%). Fifty-five percent of patients had mod-
erate to severe lower urinary tract symptoms prior to treatment
(baseline AUA 8) with a median baseline AUA of 8 (Table 2).
The median prostate volume was 38 (13–75) cc, and 9.7% had
prior procedures for benign prostatic hyperplasia (BPH). Seventy-
one percent of patients utilized alpha-antagonists prior to SBRT.
By D’Amico classification, 3 patients had low-, 19 intermediate-,
and 9 high-risk diseases. Eleven patients (35.5%) also received
androgen deprivation therapy (ADT). Seventy-five percent of
the patients were treated with 35–36.25Gy in five fractions.
The remaining 25% of the patients were treated with 19.5Gy in
three 6.5Gy fractions delivered via SBRT and had supplemental
radiation delivered using intensity-modulated radiation therapy
(IMRT) (median of 45Gy over 25 fractions). There was a bio-
chemical failure in one intermediate risk patient. At last follow-up,
26 (84%) were alive, and 5 (16%) had died from non-prostate can-
cer causes. Actuarial incidence rates of late GU and GI toxicities
are demonstrated in Figure 2. The 3-year actuarial incidence rates
ofGrade 3 GU toxicity andGrade 2 GI toxicity were 3.2% and
9.7%, respectively, and there were no Grade 4 or 5 toxicities.
Discussion
To the best of our knowledge, this is the first report on
urethrogram-directed prostate SBRT. In this study, the rates of
TABLE 1 | Baseline patient characteristics and treatment.
Patients n
N= 31





Race White 45.2% 14
Black 45.2% 14
Other 9.6% 3
Charleson comorbidity index CCI= 0 25.8% 8
CCI= 1 38.7% 12
CCI>2 35.5% 11
Contraindication to MRI Pacemaker/defibrillator 58.1% 18
Metal 41.9% 13
Prostate volume (cc) Median 38 (13–75)
Pre-txt PSA (ng/ml) Median 6.5 (0.8–148)
<10 67.7% 21
>10 and <20 12.9% 4
>20 19.4% 6





Gleason score 6 (3+3) 16.1% 5
7 (3+ 4; 4+ 3) 61.3% 19
8 (4+4) 9.7% 3
9 (4+ 5; 5+ 4) 12.9% 4
Risk groups (D’Amico) Low 9.7% 3
Intermediate 61.3% 19
High 29.0% 9
Hormone treatment Yes 35.5% 11
No 64.5% 20
Anti-coagulant use Yes 19.4% 25
No 80.6% 6
TABLE 2 | Pre-treatment quality of life (QOL) scores.






Baseline EPIC-26 summary score
Urinary domain 82.7 17.8 8.9
Incontinence domain 85.6 22.1 11.1
Irritative/obstructive domain 83.5 16.0 8.0
Bowel domain 94.0 9.4 4.7
Baseline EPIC-26 bother score
Urinary domain 68.3 30.7 15.4
Bowel domain 85.8 24.3 12.1
Baseline SF-12 score
PCS 45.6 10.2 5.1
MCS 53.8 8.3 4.2
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FIGURE 2 | Cumulative late CTCAE graded toxicities: (A) genitourinary
(GU) and (B) Gastrointestinal (GI) toxicities at each time point.
Grade 2 and higher toxicities were higher than that previ-
ously published for prostate SBRT (3–7). The etiology of this
increased toxicity is unclear but likely multifactorial. For exam-
ple, patients with high comorbidity scores have been shown to
be at increased risk of radiation therapy-related toxicity (34).
The patients included in this study were elderly with a high level
of comorbidity prior to treatment. Specifically, 33% of patients
had >2 comorbid conditions, and 19% utilized anticoagulants.
Another likely reason is the increased uncertainty in location of
the membranous urethra and anterior rectal wall with respect to
the prostate when using urethrogram-based treatment planning.
As expected, this is likely due to the poor visualization of soft
tissue structures. Yet, significant toxicity was acceptable in our
patient population. There were two bulbar urethral strictures that
were managed with dilation and did not recur. Three patients
experienced late rectal bleeding that resolved with coagulation.
All three patients were taking anticoagulants at the time of rectal
bleeding.
This study had several limitations. First, the number of patients
treated was small as contraindications to MR imaging were rare
at our institution. Our results may not be generalizable to the
overall patient population since the high rate of comorbidites in
these patients may have rendered them more prone to toxicities.
Also, pre-treatment cystoscopies were not performed due to the
risk of iatrogenic strictures. Therefore, there may have been a
higher than expected baseline rate of subclinical urethral strictures
in this patient population that remained undetected until follow-
up. Finally, long-term follow-up will be necessary to confirm our
reported late urinary effects.
Conclusion
Magnetic resonance imaging is the preferred imaging modality
to guide SBRT treatment. However, for patients with a con-
traindication to MRI, urethrogram-directed SBRT is a safe alter-
native for the treatment of localized prostate cancer. Long-term
follow-up with more patients will be necessary to confirm these
findings.
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